Hazel M. Aker is Secretary & SVP at CADENCE PHARMACEUTICALS INC (CADX). They have made 1 open-market trade across 1 company since 2011, most recently 2020-07-21.
CIK 0001265783
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $200K since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ONCT | BUY | 2020-07-21 | 2020-07-23 | $2.38 | $200K | +8.5% | -8.9% | -38.4% |
| CADX | SELL · 10b5-1 | 2013-12-16 | 2013-12-18 | $8.76 | $114K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-11-15 | 2013-11-18 | $7.41 | $385K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-07-22 | 2013-07-23 | $7.81 | $51K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-07-15 | 2013-07-17 | $7.34 | $48K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2011-11-21 | 2011-11-22 | $4.16 | $42K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.